These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7074063)

  • 21. Properties of amidinated glucagons.
    Wright DE; Rodbell M
    Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
    Liepnieks JJ; Epand RM
    Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
    Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
    Liepnieks JJ; Epand RM
    Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives.
    Heithier H; Ward LD; Cantrill RC; Klein HW; Im MJ; Pollak G; Freeman B; Schiltz E; Peters R; Helmreich EJ
    Biochim Biophys Acta; 1988 Oct; 971(3):298-306. PubMed ID: 2844291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational and biological properties of glucagon fragments containing residues 1-17 and 19-29.
    Carrey EA; Epand RM
    Int J Pept Protein Res; 1983 Sep; 22(3):362-70. PubMed ID: 6313539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipolytic and adenyl-cyclase-stimulating activity of N alpha-trinitrophenyl glucagon: comparison with other glucagon derivatives modified at the amino terminus.
    Jean-Baptiste E; Rizack MA; Epand RM
    Biosci Rep; 1982 Mar; 2(3):163-7. PubMed ID: 7066487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of an essential serine residue in glucagon: implication for an active site triad.
    Unson CG; Merrifield RB
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of antisera to des Asn28 Thr29 Homoser27-glucagon; the development of radioimmunoassay for total glucagon-like immunoreactivity in human plasma.
    Nishino T; Kodaira T; Shin S; Imagawa K; Yanaihara N; Shima K; Kumahara Y
    Endocrinol Jpn; 1981 Aug; 28(4):419-27. PubMed ID: 6897834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semisynthetic glucagon derivatives for structure-function studies.
    Hruby VJ; Wright DE; Lin MC; Rodbell M
    Metabolism; 1976 Nov; 25(11 Suppl 1):1323-5. PubMed ID: 185491
    [No Abstract]   [Full Text] [Related]  

  • 33. Iodoglucagon. Preparation and characterization.
    Desbuquois B
    Eur J Biochem; 1975 May; 53(2):569-80. PubMed ID: 1140201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon amino groups. Evaluation of modifications leading to antagonism and agonism.
    Bregman MD; Trivedi D; Hruby VJ
    J Biol Chem; 1980 Dec; 255(24):11725-31. PubMed ID: 7440567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning.
    Ahn JM; Gitu PM; Medeiros M; Swift JR; Trivedi D; Hruby VJ
    J Med Chem; 2001 Sep; 44(19):3109-16. PubMed ID: 11543679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational and biological properties of di[delta-(5-nitro-2-pyrimidyl)ornithine 17,18]glucagon. Role of the arginine residues.
    Epand RM; Liepnieks JJ
    J Biol Chem; 1983 Jan; 258(1):203-7. PubMed ID: 6294099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1004-12. PubMed ID: 6323531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1013-23. PubMed ID: 6323532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor binding of selectively labeled (Tyr-10) and (Tyr-13)-mono-125I-glucagons and competition by homologous 127I-labeled isomers.
    Pingoud V; Thole H
    Biochim Biophys Acta; 1987 Jul; 929(2):182-9. PubMed ID: 3036251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of the trinitrophenylation of the amino groups of glucagon on its conformational properties and on its ability to activate rat liver adenylyl cyclase.
    Epand RM; Wheeler GE
    Biochim Biophys Acta; 1975 May; 393(1):236-46. PubMed ID: 237568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.